We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+17.87%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$39.3M
Cap. Flow
+$15.2M
Cap. Flow %
5.83%
Top 10 Hldgs %
55.54%
Holding
65
New
16
Increased
14
Reduced
15
Closed
5
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$6.2M
2
AKAO
Achaogen Inc
AKAO
+$5.75M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.38M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.36M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.71M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$11.6M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$8.18M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.49M
4
GILD icon
Gilead Sciences
GILD
+$5.2M
5
SHPG
Shire pic
SHPG
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$21.7M 8.29%
174,022
-7,700
-4% -$921K
2016 Q4
1 quarter
BIIB icon
2
Biogen
BIIB
$34.8B
$20.6M 7.89%
75,408
+9,500
+14% +$2.69M
2016 Q4
1 quarter
REGN icon
3
Regeneron Pharmaceuticals
REGN
$82B
$17.5M 6.69%
45,130
+12,700
+39% +$4.71M
2016 Q4
1 quarter
INCY icon
4
Incyte
INCY
$23B
$17M 6.52%
127,475
+48,700
+62% +$6.2M
2016 Q4
1 quarter
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$15.1M 5.78%
124,641
-9,200
-7% -$1.19M
2016 Q4
1 quarter
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$129B
$13.4M 5.13%
122,522
+17,000
+16% +$1.5M
2016 Q4
1 quarter
SHPG
7
DELISTED
Shire pic
SHPG
$11.9M 4.55%
68,200
-27,000
-28% -$4.72M
2016 Q4
1 quarter
AMGN icon
8
Amgen
AMGN
$235B
$11M 4.21%
67,104
-13,000
-16% -$2.16M
2016 Q4
1 quarter
ILMN icon
9
Illumina
ILMN
$40.5B
$9.84M 3.77%
59,255
+1,748
+3% +$275K
2016 Q4
1 quarter
AKAO
10
DELISTED
Achaogen Inc
AKAO
$7.07M 2.7%
+280,038
New +$5.75M
2017 Q1
0 quarters
GILD icon
11
Gilead Sciences
GILD
$195B
$6.91M 2.65%
101,784
-74,000
-42% -$5.2M
2016 Q4
1 quarter
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$10.8B
$6.82M 2.61%
77,666
+2,000
+3% +$178K
2016 Q4
1 quarter
SUPN icon
13
Supernus Pharmaceuticals
SUPN
$2.3B
$6.25M 2.39%
+200,000
New +$5.36M
2017 Q1
0 quarters
BMY icon
14
Bristol-Myers Squibb
BMY
$124B
$5.33M 2.04%
+98,000
New +$5.38M
2017 Q1
0 quarters
ENTL icon
15
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$4.7M 1.8%
341,468
-61,852
-15% -$993K
2016 Q4
1 quarter
HALO icon
16
Halozyme
HALO
$13.8B
$4.64M 1.77%
358,000
+300,000
+517% +$3.79M
2016 Q4
1 quarter
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$4.51M 1.73%
170,606
+152,000
+817% +$4.01M
2016 Q4
1 quarter
KITE
18
DELISTED
Kite Pharma, Inc.
KITE
$4.35M 1.66%
55,500
+19,000
+52% +$1.17M
2016 Q4
1 quarter
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$4.09M 1.56%
+65,000
New +$4.06M
2017 Q1
0 quarters
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$13.9B
$3.92M 1.5%
27,000
+8,800
+48% +$1.15M
2016 Q4
1 quarter
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$3.62M 1.38%
23,500
-71,000
-75% -$11.6M
2016 Q4
1 quarter
DERM icon
22
DELISTED
Dermira, Inc.
DERM
$3.58M 1.37%
105,000
+60,000
+133% +$1.94M
2016 Q4
1 quarter
ADMS
23
DELISTED
Adamas Pharmaceuticals
ADMS
$3.24M 1.24%
185,234
– –
2016 Q4
1 quarter
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.87M 1.1%
108,248
+43,248
+67% +$1.07M
2016 Q4
1 quarter
EXEL icon
25
Exelixis
EXEL
$15.6B
$2.84M 1.09%
131,000
-54,000
-29% -$1.1M
2016 Q4
1 quarter
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2017 Portfolio in Review

As of Q1 2017, International Biotechnology Trust held 65 positions worth $261M, up 18% from $222M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

International Biotechnology Trust deployed $15.2M of net new capital in Q1 2017, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Achaogen Inc: 280,038 shares worth $7.07M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TESARO, Inc., an estimated $11.6M trimmed.

  • International Biotechnology Trust's largest Q1 2017 buy was Achaogen Inc: 280,038 shares worth $7.07M.
  • International Biotechnology Trust added most to Incyte in Q1 2017, an estimated $6.2M increase.
  • International Biotechnology Trust's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $11.6M.
  • International Biotechnology Trust fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $8.18M.
  • International Biotechnology Trust's ten largest holdings make up 56% of its $261M portfolio in Q1 2017.
  • International Biotechnology Trust opened 16 new positions and closed 5 in Q1 2017.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $261M.

Based on International Biotechnology Trust's 13F filing for Q1 2017, filed 2 Mar 2018.